Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 295.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (3.448%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 295.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

8 May 2019 16:41

RNS Number : 4229Y
MaxCyte, Inc.
08 May 2019
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APMUWSVRKRAVRAR
Date   Source Headline
2nd Nov 202212:05 pmRNSParticipation in Upcoming Investor Conferences
1st Nov 20229:25 amRNSTotal Voting Rights
17th Oct 20222:58 pmRNSHolding(s) in Company
12th Oct 20221:00 pmRNSNotice of Third Quarter 2022 Financial Results
3rd Oct 20229:42 amRNSTotal Voting Rights and Block Listing Return
28th Sep 20221:05 pmRNSSigning of Strategic Platform License
21st Sep 20221:05 pmRNSNew Maryland headquarters
8th Sep 20227:00 amRNSMorgan Stanley Healthcare Conference Participation
1st Sep 20224:39 pmRNSTotal Voting Rights
11th Aug 20227:00 amRNSSecond Quarter and Half-Year Results
11th Aug 20227:00 amRNSFiling of Form 10-Q for Second Quarter
2nd Aug 20222:44 pmRNSTotal Voting Rights
20th Jul 202210:00 amRNSChange of Registered Office
15th Jul 20221:01 pmRNSNotice of Results
12th Jul 20221:01 pmRNSSigning of Strategic Platform License
12th Jul 20227:00 amRNSGrant of Options
8th Jul 20225:16 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSTotal Voting Rights
30th Jun 20227:00 amRNSResult of AGM
17th Jun 20222:51 pmRNSHoldings in Company
6th Jun 20227:00 amRNSPublication of Annual Report
27th May 20227:00 amRNSNotice of AGM
16th May 20227:00 amRNSInducement Grants
10th May 20227:00 amRNSFiling of Form 10-Q
10th May 20227:00 amRNSMaxCyte Reports First Quarter Financial Results
4th May 20227:00 amRNSUpcoming Investor Conferences
29th Apr 20222:41 pmRNSTotal Voting Rights
19th Apr 20227:00 amRNSInducement Grants Under Nasdaq Listing Rule 5635
13th Apr 20227:00 amRNSDeparture of CFO and Preliminary Q1 2022 Revenue
11th Apr 20227:00 amRNSHolding(s) in Company
1st Apr 20227:02 amRNSTotal Voting Rights
28th Mar 20221:19 pmRNSGrant of Options and PDMR Dealing
28th Mar 20227:00 amRNSGrant of Options and PDMR Dealing
23rd Mar 20227:00 amRNSFourth Quarter and Full Year Financial Results
10th Mar 20227:00 amRNSMaxCyte, Names Cenk Sumen Chief Scientific Officer
8th Mar 20222:29 pmRNSHolding(s) in Company
3rd Mar 20229:45 amRNSHolding(s) in Company
1st Mar 20227:00 amRNSBlock Listing Return
24th Feb 20221:00 pmRNSNotice of Results
22nd Feb 20223:56 pmRNSHolding(s) in Company
21st Feb 20227:00 amRNSConsolidation of Trading Lines
14th Feb 20221:00 pmRNSUpcoming Investor Conferences
14th Feb 20227:00 amRNSInducement Grants Under Nasdaq Listing Rule
1st Feb 20227:00 amRNSLicense with Intima Bioscience
24th Jan 20227:30 amRNSPreliminary Unaudited Q4 & FY 2021 Revenue Results
29th Dec 20213:30 pmRNSHoldings in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
23rd Nov 20217:32 amRNSPurchase of Common Stock
17th Nov 20215:36 pmRNSExercise of options and PDMR Dealing
11th Nov 20217:00 amRNSMaxCyte Reports Third Quarter Financial Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.